SCHIZOPHRENIA

This study looks at how KarXT affects bladder function and urinary safety in 60 adults with schizophrenia over 12 months. Participants will stop their current antipsychotic medications and take KarXT instead. The goal is to see if KarXT causes any urinary problems or other side e…

This study tests a new drug called KarXT for schizophrenia in 250 Japanese adults experiencing acute psychosis. The trial has two parts: a 5-week period where some get the drug and some get a placebo, followed by a 52-week period where everyone gets the drug. The goal is to see i…

This study tests a new, slower way to increase the dose of olanzapine for people with schizophrenia. The goal is to see if this approach is safer and still controls symptoms effectively. About 120 adults with schizophrenia will take part, and researchers will monitor side effects…

This study tests the long-term safety of an experimental drug called NBI-1117568 in 600 adults with schizophrenia. Participants must stop taking other antipsychotic medications before joining. The main goal is to track any side effects that occur during treatment.

This early-phase study tests the safety and tolerability of VV119 capsules in 40 people: first in healthy adults, then in patients with schizophrenia. Researchers will monitor side effects and measure drug levels in the blood. The goal is to gather initial safety data before larg…

This study looks at whether the diabetes drug metformin can prevent blood sugar issues caused by statins (cholesterol-lowering drugs) in people with schizophrenia. About 400 adults with stable schizophrenia will take either metformin or a placebo alongside a statin for six months…

This study is testing a new medication called SEP-363856 in 100 adults with stable schizophrenia. Participants will take either 75 mg or 100 mg daily for 52 weeks to see if it is safe and tolerable. The goal is to manage symptoms, not to cure the condition.

This study tests whether valbenazine can reduce involuntary muscle movements in people with tardive dyskinesia who still have symptoms despite prior treatment. About 50 adults with schizophrenia, bipolar disorder, or major depression will take valbenazine for 24 weeks. The goal i…

This study is checking the long-term safety of a drug called KarXT (and a version called KarX-EC) in teenagers with schizophrenia and in children aged 5 to 17 with irritability linked to autism. About 400 participants who finished a prior study will take the drug and be monitored…

This study tests a program called Taking Action, where trained peers help college students with serious mental illnesses like depression, bipolar disorder, or schizophrenia learn to manage their condition. About 300 students will be randomly assigned to either the program or just…

This study tests whether clozapine, a medication for schizophrenia, can reduce violent acts better than standard treatments. It involves 280 adults with schizophrenia or schizoaffective disorder who have been violent in the past six months. Participants will receive either clozap…

This study tests whether adding brenipatide to standard schizophrenia medication is safe and effective. About 450 adults with schizophrenia will receive either brenipatide or a placebo alongside their usual care for up to 12 months. The main goal is to see if it helps with weight…

This study tests whether the drug NBI-1117568 can delay or prevent the return of schizophrenia symptoms in adults who have already responded well to the drug. About 560 participants will first receive the drug openly, then be randomly assigned to continue the drug or switch to a …

This study tests magnetic seizure therapy (MST) as a gentler alternative to electroconvulsive therapy (ECT) for people with schizophrenia that hasn't improved with medication. About 80 adults with treatment-resistant schizophrenia or schizoaffective disorder will receive MST to s…

This study is testing whether the antipsychotic clozapine works better than risperidone for people with a specific brain-based subtype (Biotype-1) of psychosis. About 524 adults with schizophrenia, schizoaffective disorder, or bipolar I disorder with psychosis will take either cl…

This study tests a non-invasive brain stimulation technique called tDCS to help people with schizophrenia who also have cannabis use disorder. 110 participants will receive 10 sessions targeting brain areas linked to control and reward. The goal is to see if this reduces cannabis…

This study looks at the long-term safety of adding KarXT (a combination of two drugs) to current antipsychotic treatment for adults with schizophrenia whose symptoms are not well controlled. About 280 participants who completed a previous study will take KarXT twice daily for 52 …

This study explores whether some cases of schizophrenia or schizoaffective disorder are actually caused by the immune system attacking the brain. Researchers are giving an immune-suppressing drug called ocrelizumab to 40 adults aged 18-35 who developed psychosis after age 15. The…

This study tests whether regular electroconvulsive therapy (ECT) sessions, given over time, can prevent a return of symptoms in people with schizophrenia that did not improve with the strongest medications. About 140 adults who already improved with a short course of ECT will eit…

This study compares a new drug combination (OLZ/SAM) to the standard drug olanzapine in teenagers with schizophrenia or bipolar I disorder. The main goal is to see if OLZ/SAM causes less weight gain over 12 weeks. About 220 teens aged 10-17 will take either OLZ/SAM or olanzapine …

This study looks at whether adding five extra services—like peer support, digital outreach, and family therapy—to standard coordinated specialty care helps people with early psychosis stay in treatment longer. About 350 participants will either receive standard care or the enhanc…

This study tests a long-acting injection of cariprazine given once a month under the skin. It is for people with schizophrenia, bipolar I disorder, or major depressive disorder who are stable on other medications. The goal is to check safety, how the drug moves in the body, and i…

This study is testing the long-term safety and effectiveness of an investigational drug called ML-007C-MA in adults with schizophrenia. About 500 participants will take the drug for up to 52 weeks to see how well it is tolerated and if it helps control symptoms. The goal is to fi…

This study tests whether tirzepatide, a drug approved for diabetes and obesity, can help people with both schizophrenia and alcohol use disorder drink less. About 108 participants will receive either tirzepatide or a placebo for 16 weeks, and researchers will track changes in hea…

This study is tracking 1500 adults with schizophrenia who are starting a new medication called KarXT (xanomeline and trospium chloride). Researchers want to see how well it works and what side effects occur in everyday medical practice, not just in a controlled lab. The goal is t…

This study is testing whether metformin, a drug typically used for diabetes, can improve cognitive problems like memory and attention in people with schizophrenia. Researchers will give 120 participants either metformin or a placebo for 24 weeks and measure changes in thinking sk…

This study compares a new version of a long-acting schizophrenia medication (paliperidone injection given every 3 months) to the approved drug Invega Trinza. About 260 Chinese adults with stable schizophrenia will receive multiple doses to see if the new formulation works similar…

This study tests a drug called KarXT in 166 teenagers (13-17 years old) with schizophrenia. The goal is to see if KarXT safely reduces symptoms like hallucinations and confusion compared to a placebo. Participants will take the drug or a dummy pill for several weeks, and doctors …

This study tests whether a long-acting injection of iloperidone can prevent schizophrenia symptoms from getting worse compared to a placebo. About 400 adults aged 18 to 65 with schizophrenia will receive either the drug or a placebo injection and be monitored for how long it take…

This study tests whether cariprazine, a medicine already used in adults, can safely reduce schizophrenia symptoms in teenagers aged 13 to 17. About 330 teens will receive either cariprazine or a placebo for 6 weeks. The main goal is to see if symptoms improve more with the active…

This study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) can help people with schizophrenia quit or reduce smoking. Fifty participants will receive active rTMS using either an F8 coil or an H coil. Researchers …

This early-stage study is testing a long-acting injectable form of KarXT, an experimental drug for schizophrenia. The main goals are to check safety and how the drug moves through the body. About 48 adults with schizophrenia will receive a single injection and be monitored closel…

This study tests a new medication, LB 102, to see if it can reduce symptoms of schizophrenia in adults experiencing a sudden worsening of their condition. About 456 participants will receive either LB 102 or a placebo for 6 weeks. The goal is to measure changes in symptom severit…

This study tests whether a prebiotic (a type of fiber that feeds good gut bacteria) can reduce inflammation and improve thinking and memory in people with schizophrenia or schizoaffective disorder. Researchers will enroll 60 adults who are stable on antipsychotic medication. The …

This study tests whether a drug that enhances NMDA receptor function can reduce negative symptoms (like lack of motivation and social withdrawal) in people with schizophrenia. Researchers want to see if the drug works differently in men versus women. The trial will enroll 90 adul…

This study tests whether adding a second drug to a standard treatment can better reduce schizophrenia symptoms. Researchers will compare the combination against the standard drug alone in 90 adults with treatment-resistant schizophrenia. The goal is to see if the combination impr…

This study tests whether MDMA (the active ingredient in ecstasy) is safe for people with schizophrenia. Many with schizophrenia struggle with social motivation, which current medications don't help. Researchers will give 20 participants low to moderate doses of MDMA in a controll…

This early-stage study tests a new extended-release tablet called LY03020 in healthy adults and people with stable schizophrenia. The main goal is to check safety and how the body processes the drug. About 40 participants will receive either the drug or a placebo, and researchers…

This study tests a community-based cognitive remediation program for 160 adults with schizophrenia or schizoaffective disorder. Participants will do computer exercises and group sessions to improve memory, problem-solving, and social skills. The goal is to see if this helps them …

This study tests whether a personalized form of brain stimulation called iTBS can help reduce schizophrenia symptoms when used alongside usual medications. Forty adults with schizophrenia will receive daily iTBS sessions for two weeks. Researchers will measure changes in symptoms…

This study tests whether yoga-based exercises can help veterans with schizophrenia, schizoaffective disorder, or bipolar 1 disorder function better in daily life—like socializing, working, and managing leisure activities. About 112 veterans will be randomly assigned to either a y…

This study tests whether a non-invasive brain stimulation technique called high-frequency transcranial alternating current stimulation (Hi-tACS) can improve cognitive problems like memory and attention in people with schizophrenia. Researchers will compare the stimulation to a fa…

This study tests a new smartphone app that uses games and stories to help people with schizophrenia improve their thinking, mood, and daily living skills. About 84 hospitalized adults will either use the app or get standard care. The goal is to see if this engaging approach works…

This study tests an experimental oral medication, ML-007C-MA, against a placebo in 300 adults hospitalized for a sudden worsening of schizophrenia symptoms. The goal is to see if the drug safely reduces psychosis severity, measured by a standard symptom scale. Participants must b…

This study tests whether a non-invasive brain stimulation technique called navigated transcranial magnetic stimulation (nTMS) can reduce negative symptoms of schizophrenia, such as lack of motivation, social withdrawal, and reduced speech. Forty adults with schizophrenia will rec…

This study is testing whether playing a special motion-controlled video game for 2 months can help improve memory, attention, and thinking speed in people with schizophrenia. The game is designed to be both fun and mentally challenging. Researchers will compare the thinking skill…

This study tests whether the experimental drug NBI-1117568 can reduce schizophrenia symptoms like hallucinations and delusions better than a placebo. About 284 adults with schizophrenia who need hospital care will take the drug or a placebo for 5 weeks while staying in the hospit…

This study tests a new drug called NBI-1117570 to see if it can improve schizophrenia symptoms like confusion, hallucinations, and mood changes. About 120 adults aged 18 to 55 who are currently hospitalized for a schizophrenia episode will receive either the drug or a placebo. Th…

This study tests an experimental drug, emraclidine, in 268 adults with schizophrenia. The goal is to see if it safely reduces symptoms like hallucinations and confused thinking. Participants take the drug or a placebo daily for up to 42 days, with regular check-ups and blood test…

This study tests whether cromoglicate, a drug used for allergies, can improve symptoms of schizophrenia when taken alongside standard medication. Researchers will enroll 160 adults aged 18-60 with schizophrenia or schizoaffective disorder. Participants will receive either cromogl…

This study tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) can improve cognitive problems and mood in people with schizophrenia, autism, bipolar disorder, depression, or Parkinson's disease. Researchers will give TMS to the …

This study tests whether adding an anti-inflammatory drug to an NMDA-enhancing agent can improve thinking and memory in people with ultra-resistant schizophrenia who haven't responded well to clozapine. About 80 adults will receive the combination or a placebo for 12 weeks. The g…

This study tests whether a new drug called GXV813 can safely reduce symptoms of schizophrenia during an acute episode. About 142 hospitalized adults aged 18-65 will receive either GXV813 or a placebo. The main goal is to see if the drug improves scores on a standard symptom scale…

This study looks at whether a very low dose of buprenorphine, a drug used for opioid addiction and depression, can boost social motivation in 40 adults with schizophrenia. Many people with this condition struggle with wanting to connect with others or avoiding social situations, …

This study tests a drug that boosts NMDA activity as a standalone treatment for schizophrenia. It is for people who refuse or cannot take antipsychotics due to side effects or poor response. The trial will measure changes in symptoms like hallucinations and social withdrawal over…

This study tests a new medication called Ulotaront (SEP-363856) to see if it can safely reduce severe symptoms like hallucinations and delusions in people with schizophrenia. About 522 adults experiencing an acute psychotic episode will receive either the drug or a placebo for 6 …

This study tests a 12-week group program called Motivation Skills Training (MST) for 80 adults with schizophrenia or schizoaffective disorder. The program teaches skills to improve motivation, goal-setting, and daily functioning. Participants are compared to a group focusing on h…

This study tests a 12-session group program called "Better Together" for 20 single adults with severe mental illness (like schizophrenia, bipolar disorder, or major depression). The program teaches communication, emotional regulation, and healthy relationship skills. Researchers …

This study tests a new medicine called NBI-1117568 to see if it can improve schizophrenia symptoms better than a placebo. About 284 adults with schizophrenia who need hospital care will take part. The main goal is to measure changes in symptoms like hallucinations and delusions a…

This study tests an experimental medicine called BXCL501 to see if it can safely reduce sudden severe agitation in children aged 10-17 with schizophrenia or bipolar disorder. About 140 participants will receive either the drug or a placebo. The goal is to quickly calm symptoms li…

This study is testing a new job training program that uses virtual reality to help people with schizophrenia improve their job interview skills and manage symptoms. The program is for 40 adults aged 20 to 55 who are motivated to work. Researchers will measure changes in symptoms …

This study tests whether adding acetazolamide to standard antipsychotic medication can reduce symptoms in people with treatment-resistant schizophrenia. About 60 adults aged 18-55 will receive either acetazolamide or a placebo for a set period, while continuing their usual medica…

This study tests whether cognitive behavioral therapy for chronic pain (CBT-CP) can help veterans with serious mental illness (like schizophrenia or bipolar disorder) who also have chronic low back pain. Researchers will measure changes in pain interference, quality of life, and …

This study tests whether a smartphone app called Kiso Mind is acceptable and helpful for people with schizophrenia or schizoaffective disorder. About 60 participants will either use the app plus their usual care, or just usual care, for 12 weeks. The goal is to see if the app is …

This study looks at whether safely stopping unnecessary anticholinergic drugs (like benztropine) can improve thinking, daily function, and quality of life in people aged 40-70 with schizophrenia or schizoaffective disorder. Participants will either continue their medication or gr…

This study tests whether breathing extra oxygen (normobaric oxygen therapy) can improve thinking, quality of life, and daily functioning in people who have had psychosis for less than five years. Twenty participants aged 15–35 will receive either oxygen or a placebo air treatment…

This study tests whether a non-invasive brain stimulation technique called TMS, applied to the cerebellum, can improve brain connectivity and thinking skills in people with schizophrenia. Forty adults aged 18-60 will receive either real or sham TMS daily for four weeks, alongside…

This study tests an experimental drug called ALTO-101, given as a skin patch, to see if it can improve cognitive problems like memory and attention in people with schizophrenia. About 82 adults with stable schizophrenia and cognitive impairment will receive both the drug and a pl…

This study tests whether a noninvasive brain stimulation technique called iTBS can improve working memory and brain activity in people with early-course schizophrenia. Researchers will use magnetic pulses and EEG to measure changes in the prefrontal cortex. 75 participants aged 1…

This study is testing whether a daily synbiotic (probiotic plus prebiotic) supplement can reduce symptoms like hallucinations and social withdrawal in people with schizophrenia or schizoaffective disorder. Researchers will compare the supplement to a placebo in 68 adults who are …

This study tests a therapy called Targeted Cognitive Training (TCT) for veterans with serious mental illnesses like schizophrenia, bipolar disorder, or PTSD. TCT uses brain exercises to improve how the brain processes information, with the goal of boosting thinking skills and dai…

This study tests whether real-time brain imaging (fMRI) can help people with schizophrenia learn to quiet the auditory hallucinations (hearing voices) that don't respond to medication. Participants will receive neurofeedback training to reduce activity in a brain area linked to v…

This study tests a virtual reality program designed to help people with psychosis improve their thinking and social skills. About 52 adults aged 18-60 with stable psychosis will use the program and do homework. The goal is to see if it's practical and helpful for daily life.

This study compares brain energy use, lactate, and glutamate levels between 75 people with schizophrenia and healthy volunteers. Participants undergo MRI and PET scans to measure these factors. The goal is to better understand the biology of schizophrenia, not to test a treatment…

This study looks at whether a gentle brain stimulation technique called tDCS changes the number of connections between brain cells in people with schizophrenia. Researchers will use special PET scans to measure these connections before and after treatment. The goal is to better u…

This study is testing a new social skills training program designed to help veterans with serious mental illness (like schizophrenia, bipolar disorder, or PTSD) improve their work relationships and job success. About 20 veterans will take part in weekly group sessions and practic…

This study looks at whether cognitive remediation—a type of brain training with coaching—can improve thinking skills, daily function, and behavior in people staying in a forensic mental health unit. About 30 adults with conditions like psychosis, ADHD, or substance use will take …

This study explores whether precise brain stimulation can lower cannabis cravings in people with schizophrenia or schizoaffective disorder. Researchers will use a type of magnetic stimulation (rTMS) on specific brain areas and measure changes in cravings and brain activity. The g…

This study aims to better understand high-level thinking problems—like motivation, self-awareness, and decision-making—in people with mental health or brain disorders such as schizophrenia, depression, bipolar disorder, Alzheimer's, and stroke. Researchers will compare 600 patien…

This study looks at how a part of the brain called the thalamus helps us switch between tasks and adapt to new situations. Researchers will scan the brains of 100 healthy adults using a powerful MRI while they complete thinking tasks. The goal is to understand why people with con…

This study aims to understand how different parts of the brain's prefrontal cortex control behaviors in people with major depression, obsessive-compulsive disorder, generalized anxiety disorder, or schizophrenia. Participants will receive transcranial magnetic stimulation (TMS) a…

This study aims to find early signs that a person having their first psychotic episode will not respond to standard treatment. Researchers will use brain imaging to look for markers that predict non-response at three months. The study includes 80 people aged 18-35 with a first ep…

This study looks at language difficulties in people with psychosis, including those with schizophrenia or early warning signs. Researchers will give language tests to 90 patients and compare results with healthy controls. The goal is to understand how language problems connect wi…

This study looks at 200 children and teens (ages 7-20) who have had a psychotic episode, such as in schizophrenia. Researchers will use interviews, brain scans, and genetic tests to group participants by their symptoms. The goal is to see if these groups can predict which antipsy…

This study is observing 300 adults with schizophrenia in the U.S. who are prescribed a new medication called KarXT (xanomeline and trospium chloride). Researchers want to learn how satisfied patients are with the treatment and whether they prefer it over other options. No new tre…

This study collects brain scans and thinking tests from 1,000 people with schizophrenia, schizoaffective disorder, and healthy volunteers. Researchers want to see how brain areas work differently during memory tasks. The goal is to better understand mental disorders, not to test …

This study looks at how feeling lonely and being socially isolated affect the brains of people with serious mental illnesses like psychosis or schizophrenia. Researchers will use surveys, daily diaries, and brain scans to understand these links. The goal is to find new ways to he…

This study looks at how attention and thinking strategies influence decision-making and brain activity in people with schizophrenia or schizoaffective disorder compared to healthy volunteers. Researchers will train participants to use a positive thinking strategy and then measure…

This study explores how people with schizophrenia or bipolar disorder experience the passage of time differently than healthy individuals. Using virtual reality games and brain wave (EEG) monitoring, researchers will measure how patients react to waiting and distractions. The goa…

This study tests whether a mild electrical current applied to the scalp (tDCS) can improve executive functions like memory, attention, and decision-making. Researchers will enroll 600 adults with conditions such as traumatic brain injury, depression, bipolar disorder, schizophren…

This study looks at whether a non-invasive brain stimulation technique called TMS can improve how quickly people with psychotic disorders (like schizophrenia or bipolar disorder) solve problems. About 95 participants will do thinking tasks and get brain scans before and after TMS…

This study tests whether a type of brain stimulation called repetitive TMS can increase natural brain inhibition in 34 people with schizophrenia. The goal is to see if this change relates to better thinking and memory. It is a small pilot study to gather early data, not a treatme…

This study uses powerful 7T MRI brain scans and visual perception tests to find biological markers for severe mental disorders like major depression, schizophrenia, and bipolar disorder. Researchers will compare 320 patients and healthy volunteers aged 18-45 to improve diagnosis …

This study uses PET brain scans to measure cannabinoid receptors in healthy volunteers and people with conditions like schizophrenia, cannabis dependence, PTSD, and opioid use disorder. The goal is to understand how these receptors differ across conditions and over time. Particip…

This study tests whether a safe, non-invasive technique called transcranial direct current stimulation (tDCS) can improve attention, learning, and memory in people with schizophrenia. Researchers will give a tiny electrical current to the forehead and measure brain activity and n…

This study looks at how people with schizophrenia experience time and sensory information differently. Researchers will use a visual illusion to test if small delays in what we see disrupt the flow of time for patients. The goal is to better understand the unusual experiences tha…

This study aims to understand why people with schizophrenia hear voices that aren't there (auditory hallucinations). Researchers think a small brain area called the inferior colliculi, which normally filters sounds, may not work properly. They will use MRI scans to compare brain …

This study tests whether a fast type of brain stimulation (accelerated TMS) can improve thinking and memory in people with schizophrenia or schizoaffective disorder who are already taking the medication clozapine. About 30 adults aged 18-50 will receive both real and fake stimula…

This study looks at how people with schizophrenia use the passage of time to predict and prepare for a touch sensation. Researchers will measure finger movements and brain signals to find objective markers of time perception problems. The goal is to develop a test that could help…

This study uses a safe, noninvasive technique called transcranial magnetic stimulation (TMS) to understand how hallucinations happen in people with schizophrenia or schizoaffective disorder. Researchers will stimulate a specific brain circuit and measure changes in brain activity…

This study looks at 300 people with first-episode schizophrenia (who haven't taken medication yet) and healthy volunteers. Researchers will examine tiny particles called exosomes in the blood to see if their microRNA content is linked to cognitive (thinking) problems. The goal is…

This study looks at 320 people who recently developed psychosis (like schizophrenia or bipolar I) to see if brain scans, eye-tracking, and genetics can predict who will get better with treatment. Participants attend four visits over a year, providing DNA, EEG, and MRI data. The g…

This study looks at 200 people with schizophrenia who are starting clozapine, a medication for tough-to-treat cases. Researchers will check brain scans, spinal fluid, and blood before and after 12 weeks of treatment to find markers that show why clozapine works. The goal is to le…